Destiny Pharma (GB:DEST) has released an update.
Destiny Pharma PLC, a clinical-stage biotech company, has reported a reduced loss before tax to £6.4 million for 2023 and has announced strategic reviews to advance its XF-73 nasal program through Phase 3 trials. The company is engaging potential partners for licensing deals and has confirmed the commercial potential of XF-73 nasal, which has shown effectiveness against resistant bacterial strains. Additionally, Destiny Pharma has entered a lucrative deal with Sebela Pharmaceuticals for its NTCD-M3 program, potentially worth up to $570 million plus royalties.
For further insights into GB:DEST stock, check out TipRanks’ Stock Analysis page.
